diabetic kidney disease(DKD)
Conditions
Interventions
GQ decoction group (group D):Lifestyle interventions+Irbesartan(Basic treatment)+GQ decoction
Conventional dose GQ formula granule group (group M):Lifestyle interventions+Irbesartan(Basic treatment)+Conventional dose GQ formula granule
GQ formula granule simulator group (group P):Lifestyle interventions+Irbesartan(Basic treatment)+GQ formula granule simulator
Low-dose GQ formula granule group (group L):Lifestyle interventions+Irbesartan(Basic treatment)+Low-dose GQ formula
Sponsors
Wuxi Traditional Chinese Medicine Hospital affliated to Nanjing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Meeting the western medical diagnostic criteria for diabetic nephropathy. (2) Aged between 18 and 70 years old regardless of gender. (3) Blood pressure = 160/95 mmHg. (4) Fasting blood glucose (FPG) = 14 mmol/L and glycosylated hemoglobin (HbA1c) = 8%. (5) Creatinine clearance rate is 30 - 59 ml/min or 24-hour urine protein quantification (24hUPro) is 0.15 - 3.49 g/24h. (6) Signing the informed consent form voluntarily participating in the trial and being able to take medicine and undergo examinations as agreed.
Exclusion criteria
Exclusion criteria: (1) Those with other types of diabetes except type 2 diabetes and those who have had acute complications such as diabetic ketoacidosis and hyperglycemic hyperosmolar coma recently. (2) Pregnant or lactating women. (3) Those with proteinuria caused by other diseases such as chronic glomerulonephritis IgA nephropathy and membranous nephropathy. (4) Those with malignant tumors severe infections those with cardiac and pulmonary insufficiency and those who have received hemodialysis and after kidney transplantation. (5) Those with abnormal liver function more than three times higher than the normal value. (6) Patients with a history of alcohol and drug abuse and those with mental disorders. (7) Those with contraindications to drug use or allergic to drugs. (8) Those who have had obvious renal function damage caused by daily oral drugs. (9) Those who have used ACEI and ARB drugs within nearly 4 weeks. (10) Those who have started using SGLT2i GLP-1RA and MRA drugs within nearly 4 weeks. (11) Those who participate in other clinical trials during the treatment period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mALb;24hUPro;UACR;DKD staging and grading assessment form; | — |
Secondary
| Measure | Time frame |
|---|---|
| IMT;HbA1c;AI;DKD symptom score form;Fundus examination;HDL;TG;Cr;BUN;TC;2hPBG;Traditional Chinese medicine syndrome score form for DKD;FBG;LDL-C;eGFR;CysC; | — |
Countries
China
Contacts
Public ContactXIAOFENG GU
Wuxi Traditional Chinese Medicine Hospital affliated to Nanjing University of Chinese Medicine
Outcome results
None listed